Bloomberg TV: Sir Andrew Witty, CEO, GSK, discusses antibiotic resistance in Davos


Andrew Witty, Chief Executive Officer, GSK, discusses antibiotic effectiveness, the issues surrounding drug pricing and corporate inversions. He speaks to Bloomberg's Jonathan Ferro and Hans Nichols on "Countdown" from the World Economic Forum in Davos, Switzerland, January 2016.

Related tags

Explore more features

Graphic of chromosomes

Innovation

Igniting a revolution in scientific research and development

Patrick Vallance

How we do business

How we are bringing science to life | GSK R&D

Patrick Vallance is something of a rare breed: a game-keeper turned poacher; an academic who's moved over into industry. And not just any industry, but the pharmaceutical industry.

Bioelectronic pathways

Behind the science

Leading future science | GSK medical science

Our challenge was to accelerate 10 years to 10 months, fast tracking our research and development.

Back to top